XBIT earnings analysis
What we found in XBIT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided excerpt does not contain the June 30, 2026 income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A, so revenue, margins, EPS, cash flow, liquidity, and operating trends cannot be quantified reliably. Management reported effective disclosure and financial-reporting controls as of June 30, 2026, with no material control changes during the quarter. The company also reported no material changes to the risk factors included in the December 31, 2025 Form 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remain effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, under Exchange Act Rules 13a-15(e) and 15d-15(e).
- Financial reporting controls effective
- Management concluded that internal control over financial reporting was effective as of June 30, 2026, providing reasonable assurance regarding reliable financial reporting under GAAP.
- No material control changes
- The company reported no change during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Risk framework remains unchanged
- The company reported no material changes to the risk factors in its Annual Report on Form 10-K for the year ended December 31, 2025. The filing nevertheless states that the disclosed risks could materially and adversely affect the business, financial condition, results of operations, and common-stock trading price.
What they said about what is next.
The provided filing excerpt contains no quantitative revenue or EPS outlook. The excerpt does not include the MD&A or the financial statements needed to assess current-period guidance.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- XBiotech reported a net loss of $5.5 million for Q1 2026, a decrease from the $10.9 million loss in Q1 2025, reflecting improved cost management. The company continues to have no product revenue, forecasting significant…
- 10-K · April 29, 2026
- XBiotech remains focused on developing its True Human™ monoclonal antibodies, with a strategic emphasis on areas such as oncology and rheumatology. Despite ongoing R&D efforts, the company has not yet generated product…
- 10-K · March 13, 2026
- XBiotech positions itself as a fully integrated developer of True Human™ monoclonal antibodies with a strategic focus on anti‑IL‑1α programs (oncology, rheumatology, neurology) and an infectious disease pipeline. The…
- 10-K · March 18, 2025
- XBiotech is a clinical-stage biopharma focused on True Human™ monoclonal antibodies (notably anti‑IL‑1α programs). The company reports a promising signal from a 60‑subject pancreatic cancer (Natrunix) study (preliminary…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XBIT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever